Pharmacology of the receptors for the phorbol ester tumor promoters: Multiple receptors with different biochemical properties

Biochemical Pharmacology

Volumn 60, Issue 10, 2000, Pages 1417-1424

  Kazanietz, Marcelo G ^a   Caloca, María J ^a   Eroles, Pilar ^a   Fujii, Teruhiko ^a   García Bermejo, María L ^a   Reilly, Muredach ^a   Wang, HongBin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chimaerins; Diacylglycerol; Phorbol esters; PKC; RasGRP

Indexed keywords

CELL RECEPTOR; CHIMERIN; DIACYLGLYCEROL; DIACYLGLYCEROL DERIVATIVE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; ISOENZYME; PHORBOID RECEPTOR; PHORBOL ESTER; PHORBOL ESTER DERIVATIVE; PROTEIN KINASE C; PROTEIN MUNC 13; PROTEIN RASGRP; PROTEIN UNC 13; RAC PROTEIN; TUMOR PROMOTER; UNCLASSIFIED DRUG;

BINDING SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME REGULATION; HORMONE RECEPTOR TRANSLOCATION; HUMAN; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; RECEPTOR BINDING; REVIEW; SECOND MESSENGER; TUMOR PROMOTION;

EID: 0034670173     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00470-6     Document Type: Article

References (65)

1. Blumberg P.M. Complexities of the protein kinase C pathway. Mol Carcinog. 4:1991;339-344.
2. DiGiovanni J. Modification of multistage skin carcinogenesis in mice. Prog Exp Tumor Res. 33:1991;192-229.
3. Blumberg P.M. Protein kinase C as the receptor for the phorbol ester tumor promoters Sixth Rhoads Memorial Award Lecture . Cancer Res. 48:1988;1-8.
4. Szallasi Z., Krsmanovic L., Blumberg P.M. Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. Cancer Res. 53:1993;2507-2512.
5. Hennings H., Blumberg P.M., Pettit G.R., Herald C.L., Shores R., Yuspa S.H. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis. 8:1987;1343-1346.
6. Castagna M., Takai Y., Kaibuchi K., Sano K., Kikkawa U., Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 257:1982;7847-7851.
7. Leach K.L., James M.L., Blumberg P.M. Characterization of a specific phorbol ester aporeceptor in mouse brain cytosol. Proc Natl Acad Sci USA. 80:1983;4208-4212.
8. Sharkey N.A., Leach K.L., Blumberg P.M. Competitive inhibition by diacylglycerol of specific phorbol ester binding. Proc Natl Acad Sci USA. 81:1984;607-610.
9. 3H]phorbol 12,13-dibutyrate binding. Cancer Res. 45:1985;19-24.
10. Johnson J.E., Zimmerman M.L., Daleke D.L. Lipid structure and not membrane structure is the major determinant in the regulation of protein kinase C by phosphatidylserine. Biochemistry. 37:1998;12020-12025.
11. ++ dependency of phorbol ester receptors. J Cell Biochem. 27:1985;255-265.
12. Kazanietz M.G., Barchi J.J. Jr, Omichinski J.G., Blumberg P.M. Low affinity binding of phorbol esters to PKC and its cysteine-rich region in the absence of phospholipids. J Biol Chem. 270:1995;14679-14684.
13. Jaken S. Protein kinase C isozymes and substrates. Curr Opin Cell Biol. 8:1996;168-173.
14. Newton A.C. Regulation of protein kinase C. Curr Opin Cell Biol. 9:1997;161-167.
15. Mellor H., Parker P.J. The extended protein kinase C superfamily. Biochem J. 332:1998;281-292.
16. Ron D., Kazanietz M.G. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J. 13:1999;1658-1676.
17. Valverde A.M., Sinnett-Smith J., Van Lint J., Rozengurt E. Molecular cloning and characterization of protein kinase D A target for diacylglycerol and phorbol esters with a distinctive catalytic domain . Proc Natl Acad Sci USA. 91:1994;8572-8576.
18. Johannes F.J., Prestle J., Eis S., Oberhagemann P., Pfizenmaier K. PKCμ is a novel, atypical member of the protein kinase C family. J Biol Chem. 269:1994;6140-6148.
19. Hayashi A., Seki N., Hattori A., Kozuma S., Saito T. PKCν, a new member of the protein kinase C family, composes a fourth subfamily with PKCμ Biochim Biophys Acta. 1450:1999;99-106.
20. Kazanietz M.G., Areces L.B., Bahador A., Mischak H., Goodnight J., Mushinski J.F., Blumberg P.M. Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. Mol Pharmacol. 44:1993;298-307.
21. Ono Y., Fujii T., Igarashi K., Kuno T., Tanaka C., Kikkawa U., Nishizuka Y. Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence. Proc Natl Acad Sci USA. 86:1989;4868-4871.
22. Quest A.F.G., Bardes E.S.G., Bell R.M. A phorbol ester binding domain of protein kinase Cγ. Deletion analysis of the Cys2 domain defines a minimal 43-amino acid peptide. J Biol Chem. 269:1994;2961-2970.
23. Kazanietz M.G., Bustelo X.R., Barbacid M., Kolch W., Mischak H., Wong G., Pettit G.R., Bruns J.D., Blumberg P.M. Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C ξ and the vav and c-raf proto-oncogene products. J Biol Chem. 269:1994;11590-11594.
24. Kazanietz M.G., Wang S., Milne G.W.A., Lewin N.E., Liu H.L., Blumberg P.M. Residues in the second cysteine-rich region of protein kinase C δ relevant to phorbol ester binding as revealed by site-directed mutagenesis. J Biol Chem. 270:1995;21852-21859.
25. Zhang G., Kazanietz M.G., Blumberg P.M., Hurley J.H. Crystal structure of the cys2 activator-binding domain of protein kinase Cδ in complex with phorbol ester. Cell. 81:1995;917-924.
26. Ichikawa S., Hatanaka H., Takeuchi Y., Ohno S., Inagaki F. Solution structure of cysteine-rich domain of protein kinase C alpha. J Biochem (Tokyo). 117:1995;566-574.
27. Xu R.X., Pawelczyk T., Xia T.-H., Brown S.C. NMR structure of a protein kinase C-γ phorbol-binding domain and study of protein-lipid micelle interactions. Biochemistry. 36:1997;10709-10717.
28. Wang S., Liu M., Lewin N.E., Lorenzo P.S., Bhattacharrya D., Qiao L., Kozikowski A.P., Blumberg P.M. Probing the binding of indolactam-V to protein kinase C through site-directed mutagenesis and computational docking simulations. J Med Chem. 42:1999;3436-3446.
29. Hannun Y.A., Loomis C.R., Bell R.M. Activation of protein kinase C by Triton X-100 mixed micelles containing diacylglycerol and phosphatidylserine. J Biol Chem. 260:1985;10039-10043.
30. Hunn M., Quest A. Cysteine-rich regions of protein kinase Cδ are functionally non-equivalent. Differences between cysteine-rich regions of non-calcium-dependent protein kinase Cδ and calcium-dependent protein kinase Cγ FEBS Lett. 400:1997;226-232.
31. Irie K., Yanai Y., Oie K., Ishizawa J., Nakagawa Y., Ohigashi H., Wender P.A., Kikkawa U. Comparison of chemical characteristics of the first and the second cysteine-rich domains of protein kinase C gamma. Bioorg Med Chem. 5:1997;1725-1737.
32. Slater S.J., Ho C., Kelly M.B., Larkin J.D., Taddeo F.J., Yeager M.D., Stubbs C.D. Protein kinase Cα contains two activator binding sites that bind phorbol esters and diacylglycerols with opposite affinities. J Biol Chem. 271:1996;4627-4631.
33. Slater S.J., Taddeo F.J., Mazurek A., Stagliano B.A., Milano S.K., Kelly M.B., Ho C., Stubbs C.D. Inhibition of membrane lipid-independent protein kinase Cα activity by phorbol esters, diacylglycerols, and bryostatin-1. J Biol Chem. 273:1998;23160-23168.
34. Iglesias T., Matthews S., Rozengurt E. Dissimilar phorbol ester binding properties of the individual cysteine-rich motifs of protein kinase D. FEBS Lett. 437:1998;19-23.
35. Szallasi Z, Bögi K, Gohari S, Biro T, Acs P and Blumberg PM, Non-equivalent roles for the first and second zinc fingers of protein kinase Cδ. Effect of their mutation on phorbol ester-induced translocation in NIH 3T3 cells. J Biol Chem 271: 18299-18301, 1996.
36. Bögi K., Lorenzo P.S., Szállási Z., Ács P., Wagner G.S., Blumberg P.M. Differential selectivity of ligands for the C1a and C1b phorbol ester binding domains of protein kinase Cδ Possible correlation with tumor-promoting activity . Cancer Res. 58:1998;1423-1428.
37. Lorenzo P.S., Bögi K., Hughes K.M., Beheshti M., Bhattacharyya D., Garfield S.H., Pettit G.R., Blumberg P.M. Differential roles of the tandem C1 domains of protein kinase C δ in the biphasic down-regulation induced by bryostatin 1. Cancer Res. 59:1999;6137-6144.
38. Shieh H.L., Hansen H., Zhu J., Riedel H. Differential protein kinase C ligand regulation detected in vivo by a phenotypic yeast assay. Mol Carcinog. 12:1995;166-176.
39. Hurley J.H., Newton A.C., Parker P.J., Blumberg P.M., Nishizuka Y. Taxonomy and function of C1 protein kinase C homology domains. Protein Sci. 6:1997;477-480.
40. Mott H.R., Carpenter J.W., Zhong S., Ghosh S., Bell R.M., Campbell S.L. The solution structure of the Raf-1 cysteine-rich domain A novel Ras and phospholipid binding site . Proc Natl Acad Sci USA. 93:1996;8312-8317.
41. Gulbins E., Coggeshall K.M., Baier G., Telford D., Langlet C., Baier-Bitterlich G., Bonnefoy-Berard N., Burn P., Wittinghofer A., Altman A. Direct stimulation of Vav guanine nucleotide exchange activity for Ras by phorbol esters and diglycerides. Mol Cell Biol. 14:1994;4749-4758.
42. Areces L.B., Kazanietz M.G., Blumberg P.M. Close similarity of baculovirus-expressed n-chimaerin and protein kinase Cα as phorbol ester receptors. J Biol Chem. 269:1994;19553-19558.
43. Caloca M.J., Fernandez N., Lewin N.E., Ching D., Modali R., Blumberg P.M., Kazanietz M.G. β2-Chimaerin is a high affinity receptor for the phorbol ester tumor promoters. J Biol Chem. 272:1997;26488-26496.
44. Caloca M.J., Garcia-Bermejo M.L., Blumberg P.M., Lewin N.L., Kremmer E., Mischak H., Wang S., Nacro K., Bienfait B., Marquez V.E., Kazanietz M.G. β2-Chimaerin is a novel target for diacylglycerol Binding properties and changes in subcellular localization mediated by ligand binding to its C1 domain . Proc Natl Acad Sci USA. 96:1999;11854-11859.
45. Ebinu J.O., Bottorff D.A., Chan E.Y.W., Stang S.L., Dunn R.J., Stone J.C. RasGRP, a Ras guanyl nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Science. 280:1998;1082-1086.
46. Tognon C.E., Kirk H.E., Passmore L.A., Whitehead I.P. Der CJ and Kay RJ, Regulation of RasGRP via a phorbol ester-responsive C1 domain. Mol Cell Biol. 18:1998;6995-7008.
47. Lorenzo P.S., Behshti M., Pettit G.R., Stonne J.C., Blumberg P.M. The guanine nucleotide exchange factor RasGRP is a high affinity target for diacylglycerol and phorbol esters. Mol Pharmacol. 57:2000;840-846.
48. Maruyama I.N., Brenner S. Phorbol ester/diacylglycerol-binding protein encoded by the unc-13 gene of Caenorhabditis elegans. Proc Natl Acad Sci USA. 88:1991;5729-5733.
49. Betz A., Ashery U., Rickmann M., Augustin I., Neher E., Südhof T.C., Rettig J., Brose N. Munc13-1 is a presynaptic phorbol ester receptor that enhances neurotransmitter release. Neuron. 21:1998;123-136.
50. Duncan R.R., Betz A., Shipston M.J., Brose N., Chow R.H. Transient, phorbol ester-induced DOC2-Munc13 interactions in vivo. J Biol Chem. 274:1999;27347-27350.
51. Song Y., Ailenberg M., Silverman M. Human munc13 is a diacylglycerol receptor that induces apoptosis and may contribute to renal cell injury in hyperglycemia. Mol Biol Cell. 10:1999;1609-1619.
52. Kazanietz M.G., Lewin N.E., Bruns J.D., Blumberg P.M. Characterization of the cysteine-rich region of the Caenorhabditis elegans protein Unc-13 as a high affinity phorbol ester receptor. Analysis of ligand-binding interactions, lipid cofactor requirements, and inhibitor sensitivity. J Biol Chem. 270:1995;10777-10783.
53. Kawasaki H., Springett G.M., Toki S., Canales J.J., Harlan P., Blumenstiel J.P., Chen E.J., Bany I.A., Mochizuki N., Ashbacher A., Matsuda M., Housman D.E., Graybiel A.M. A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. Proc Natl Acad Sci USA. 95:1998;13278-13283.
54. Mochly-Rosen D., Gordon A.S. Anchoring proteins for protein kinase C A means for isozyme selectivity . FASEB J. 12:1998;35-42.
55. Goodnight J.A., Mischak H., Kolch W., Mushinski J.F. Immunocytochemical localization of eight protein kinase C isozymes overexpressed in NIH 3T3 fibroblasts. Isoform-specific association with microfilaments, Golgi, endoplasmic reticulum, and nuclear and cell membranes. J Biol Chem. 270:1995;9991-10001.
56. Li L., Lorenzo P.S., Bogi K., Blumberg P.M., Yuspa S.H. Protein kinase Cδ targets mitochondria, alters mitochondrial membrane potential, and induces apoptosis in normal and neoplastic keratinocytes when overexpressed by an adenoviral vector. Mol Cell Biol. 19:1999;8547-8558.
57. Wang Q.J., Bhattacharyya D., Garfield S., Nacro K., Marquez V.E., Blumberg P.M. Differential localization of protein kinase C δ by phorbol esters and related compounds using a fusion protein with green fluorescent protein. J Biol Chem. 274:1999;37233-37239.
58. Wang Q.J., Fang T.-W., Fenick D., Garfield S., Bienfait B., Marquez V.E., Blumberg P.M. The lipophilicity of phorbol esters as a critical factor in determining the pattern of translocation of protein kinase C δ fused to green fluorescent protein. J Biol Chem. 275:2000;12136-12146.
59. Marquez V.E., Nacro K., Benzaria S., Lee J., Sharma R., Teng K., Milne G.W., Bienfait B., Wang S., Lewin N.E., Blumberg P.M. The transition from a pharmacophore-guided approach to a receptor-guided approach in the design of potent protein kinase C ligands. Pharmacol Ther. 82:1999;251-261.
60. Nacro K., Bienfait B., Lewin N.E., Blumberg P.M., Marquez V.E. Diacylglycerols with lipophilically equivalent branched acyl chains display high affinity for protein kinase C (PK-C). A direct measure of the effect of constraining the glycerol backbone in DAG lactones. Bioorg Med Chem Lett. 10:2000;653-655.
61. Nacro K., Bienfait B., Lee J., Han K.C., Kang J.H., Benzaria S., Lewin N.E., Bhattacharyya D.K., Blumberg P.M., Marquez V.E. Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C? J Med Chem. 43:2000;921-944.
62. Caponigro F., French R.C., Kaye S.B. Protein kinase C A worthwhile target for anticancer drugs? Anticancer Drugs. 8:1997;26-33.
63. Gonzalez R., Ebbinghaus S., Henthorn T.K., Miller D., Kraft A.S. Treatment of patients with metastatic melanoma with bryostatin-1 - A phase II study. Melanoma Res. 9:1999;599-606.
64. Varterasian M.L., Mohammad R.M., Shurafa M.S., Hulburd K., Pemberton P.A., Rodriguez D.H., Spadoni V., Eilender D.S., Murgo A., Wall N., Dan M., Al-Katib A.M. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 6:2000;825-828.
65. Han Z.T., Zhu X.X., Yang R.Y., Sun J.Z., Tian G.F., Liu X.J., Cao G.S., Newmark H.L., Conney A.H., Chang R.L. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia Preliminary studies on therapeutic efficacy and toxicity . Proc Natl Acad Sci USA. 95:1998;5357-5361.